FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference Survey

FF/UMEC/VI: Qualitative Interviews and Discrete Choice Experiment(s) Evaluating the Perceived Benefits of the Features of FF/UMEC/VI (Single Inhaler Triple Therapy) Treatment in the UK, US and Germany

Three main classes of inhaled treatment exist for chronic obstructive pulmonary disease (COPD): Beta2-adrenergic agonists (which may be short (SABA) or long (LABA) acting), long-acting muscarinic acetylcholine receptor antagonists (LAMA), and inhaled corticosteroids (ICS). For subjects at higher risk of exacerbation, treatment with all these three classes of medication is recommended. This study aims to explore the potential utility of a device called single inhaler triple combination or fluticasone furoate/ umeclidinium/ vilanterol (FF/UMEC/VI) inhaler containing all three groups of compound. This is a mixed methods study with a qualitative phase and a quantitative Discrete Choice Experiment (DCE) phase and will be conducted in four stages: qualitative concept elicitation, DCE development, DCE piloting and testing, and conduct of the DCE. The study will conducted in the United Kingdom (UK), United States (US) and Germany and approximately 573 subjects with COPD will be included.

Study Overview

• Status: Completed
• Conditions: Pulmonary Disease, Chronic Obstructive
• Intervention / Treatment: Other: Telephone interviews; Other: In-person focus groups; Other: DCE surveys- cognitive interviews; Other: Modified DCE; Other: Online DCE survey

• Study Type: Observational
• Enrollment (Actual): 634

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, EC4Y 0AY
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Subjects with COPD who may be receiving any combination of dual or triple therapy treatment will be included in the study.

Description

Inclusion Criteria:

• Diagnosis of COPD, self-reported.
• Age: More than or equal to 40 years.
• Moderate to severe COPD, indicated by a COPD Assessment Test (CAT) score of greater than or equal to 10 or Modified Medical Research Council (MMRC) score of greater than or equal to 2.
• Currently prescribed and receiving one of the following treatment types: ICS/LABA; LABA/LAMA; ICS/LABA/LAMA (triple therapy); LAMA.
• Currently resident in the UK, US or Germany.
• Adequate written and oral fluency in language of country of residence.
• Willing and able to understand the study and provide informed consent.
• Has access to the internet (Cognitive interviews and DCE survey only).

Exclusion Criteria:

• Has taken part in any other stage of this study.
• Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD).
• Any co-morbidity that would inhibit the ability to provide informed consent or allow participation in a telephone of face-to-face interview.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

5

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Subjects included in telephone interviews; Approximately 10 subjects with COPD per country will be included in qualitative concept elicitation telephone interviews.	Other: Telephone interviews; Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
Subjects included in in-person focus groups; 1 in-person focus-group per country including up to 5 subjects with COPD will be included in the qualitative analysis.	Other: In-person focus groups; Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
Subjects included in DCE surveys- cognitive interviews; Up to six subjects with COPD in each of the UK, US and Germany will be asked to complete and provide feedback on the surveys.	Other: DCE surveys- cognitive interviews; Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
Subjects included in modified DCEs; Up to 20 subjects with COPD in each country will be included in pilot testing of the modified DCEs.	Other: Modified DCE; The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
Subjects included in Final DCE; 150 subjects with COPD in each of the UK, US and Germany will be included in the final online market specific DCE survey.	Other: Online DCE survey; An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of the key relevant attributes of COPD treatment	The key attributes considered to be most important to subjects with COPD when making treatment choices will be assessed using the data from the subject interviews and focus groups.	Up to 368 hours
Evaluation of the preferences, priorities and treatment goals of subjects with COPD for inhaled treatments	The probability of choosing one treatment over another will be evaluated using DCE survey questionnaire.	Up to 368 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of the relative appeal of different treatment approaches	The burden of COPD, priorities in terms of symptoms and treatment effect, goals and preferences of subjects will be analyzed.	Up to 371 hours
Estimation of the relative importance of each attribute	The DCE online survey will be used to assess the relative importance of treatment attributes and priorities.	Up to 371 hours

Collaborators and Investigators

• Sponsor: GlaxoSmithKline
• Collaborators: ICON plc

Publications and helpful links

Helpful Links

• Results for study 206455 can be found on the GSK Clinical Study Register.

Study record dates

Study Major Dates

• Study Start (Actual): February 20, 2017
• Primary Completion (Actual): February 23, 2018
• Study Completion (Actual): February 23, 2018

Study Registration Dates

• First Submitted: February 6, 2017
• First Submitted That Met QC Criteria: February 6, 2017
• First Posted (Estimate): February 8, 2017

Study Record Updates

• Last Update Posted (Actual): March 9, 2020
• Last Update Submitted That Met QC Criteria: March 5, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Keywords: COPD; Qualitative; Triple therapy; DCE
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: 206455

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No